Core Insights - The Phase 3 trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia did not demonstrate a favorable clinical benefit compared to chemotherapy alone, with median overall survival of 9.3 months versus 14.3 months [1][7] - Apollomics announced a write-down of the intangible asset related to the uproleselan program and expects future expenses for this program to be less than $500,000 [2] Company Overview - Apollomics Inc. is a late-stage clinical biopharmaceutical company focused on developing oncology drug candidates for difficult-to-treat cancers [7][9] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial across multiple countries [9]
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia